

CASE REPORT

Open Access



Bifocal malakoplakia in a patient living with HIV: case report

Mohammed Alsaeed^{1,4*} , Mohamed Mursi¹, Nazik Eltayeb¹, Hadi Kuriry², Salafa Albaghli³ and Yasir Alrusayni³

Abstract


Background Malakoplakia is a rare chronic granulomatous disease characterized by the presence of Michaelis-Gutmann bodies (MGBs) within histiocytic aggregates. It predominantly affects immunocompromised individuals, including those living with Human Immunodeficiency Virus (HIV).

Case Presentation We present a unique case of bifocal malakoplakia in a 49-year-old man, previously with Coronavirus disease 2019 (COVID-19) and HIV positive, presented with respiratory symptoms, weight loss, and lymphadenopathy. He had various infections including Non-Tuberculous Mycobacteria (NTM), Cytomegalovirus (CMV), and Candida, with evolving lung and gastrointestinal issues. Despite treatment attempts, he deteriorated due to respiratory distress, multi-organ failure, and coagulopathy, leading to his unfortunate demise.

Conclusion This report presents a distinctive and complex case of malakoplakia in an HIV-positive patient, a rare inflammatory disorder originally described by Michaelis and Gutmann in 1902. The hallmark Michaelis-Gutmann organisms were observed, confirming the diagnosis. While typically affecting the urinary tract, this case demonstrates the exceptional ability of malakoplakia to manifest in various organ systems, including pulmonary, gastrointestinal, and more. Although *Escherichia coli* is a prevalent associated pathogen, the exact cause remains elusive. Treatment, often involving surgical excision and antibiotic therapy, underscores the challenging nature of managing this condition in immunocompromised individuals.

Keywords Malakoplakia, HIV, CMV, *Rhodococcus equi*, SARS-CoV-2

Background



*Correspondence:

Mohammed Alsaeed
mohalsaheed@live.com

¹Medicine department, Infectious disease division, Prince Sultan Military Medical City, P.O.Box 7897, Riyadh 11159, Saudi Arabia

²Multi Organ Transplant Center of Excellence, King Fahad Specialist Hospital, Dammam, Saudi Arabia

³Pathology department, Prince Sultan Military Medical City, Riyadh, Saudi Arabia

⁴College of Medicine, Alfaisal University, Riyadh, Saudi Arabia



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Laboratory results

Test/ Normal range	First admission March 2021	Second Admission June 2021
WBCs (4-1110 ⁹ /l)	10.1	9.04
Hemoglobin (125–180)	86 g/L	54 g/L
Mean cell volume(75–95)	85 fl.	88 fl.
Platelets count (150–350 1110 ⁹ /l)	342	143
Neutrophils count (1.8–7.5 10 ⁹ /l)	8.8	7.8
Lymphocytes count (1.5-4.0 10 ⁹ /l)	0.6	0.39
Sodium (136–145)	133 mmol/L	131 mmol/L
Potassium (3.5–5.1)	3.5 mmol/L	3.4 mmol/L
Urea (2.8–8.1)	6.6 mmol/L	6.0 mmol/L
Creatinine(59–104)	51 mmol/L	51 mmol/L
Corrected Calcium (2.15–2.5)	2.62 mmol/L	2.42 mmol/L
Albumin (35–52)	21 g/L	17 g/L
Total bilirubin (2–21)	20 umol/L	11 umol/L
Alkaline phosphatase(40–129)	511 U/L	447 U/L
Alanine aminotransferase(5–41)	60 U/L	23 U/L
Gamma GT (8–61)	189 U/L	Not done
C-reactive protein (0–6)	160 mg/L	117.36 mg/L
ESR (0–15)	113 mm/hr	102 mm/hr
Procalcitonin (0.5)	0.48 ug/L	0.34 ug/L
COVID19 PCR	Positive	Positive
ANA	Positive	Not done
ANCA	Positive p-ANCA Negative c-ANCA	Not done

Case presentation




Fig. 1 Image (i) A chest radiograph upon arrival of the first admission, demonstrates a right lower zone infiltration with a small cavity lesion. Image (ii) CT chest of the first admission, demonstrate a 2.7 × 3 cm heterogenous enhancing soft tissue lesion compressing the right lower lobe segmental bronchus (red arrows). Image (iii) CT Chest of the second admission, show the evolving right lower lobe mass reaching 10.3 × 10.5 cm making more compression on the right lower segmental main bronchus (green arrows) with the presence of air pockets as demonstrated as shown in images

Table 2 Bronchoalveolar lavage (BAL) results of the first admission

Bacterial culture	No growth
Fungal culture	<i>Candida glabrata</i>
Acid fast bacilli smear	Three sample were taken and two turned to be weakly positive
TB PCR	Negative
TB culture	Pending (turned to be positive for Non-Tuberculous Mycobacterium after 8 weeks in August 2021 and the patient passed away in July 2021).
Respiratory panel PCR	Negative
Cytology	Negative for malignancy and special fungal stain turned to be negative.





Fig. 2 Gross endoscopic appearance of the right colon showing the cecal base at ileocecal valve with deformed looking. Multiple ulcers ranging between 5 mm and 1 cm in diameter with noticed with raised edges and whitish base. Some ulcers were oozing blood and others were covered by clots




Fig. 3 (1) Malakoplakia. High magnification view showing epithelioid histiocytes with abundant eosinophilic cytoplasm and intracytoplasmic round basophilic targetoid inclusions (Michaelis-Gutmann bodies) (arrows), diagnostic of malakoplakia(Lung). (2) Malakoplakia. High magnification view showing colonic epithelium with underlying epithelioid histiocytes (arrow) with abundant eosinophilic cytoplasm(Colon). (3) The Michaelis-Gutmann bodies are highlighted with a von Kossa stain. (4) Immunostaining for CMV is POSITIVE

?P. \ Z a t P aa a q . q . Z j . p j . a Z j .
j . s . a j Z Z j a . x . R . a a P Z d j .
a P Z d j . Z Z p . a t q Z d j .
s . j . j . Z j . a . l j . t . a t q Z p . h j . a
s . j . Z j . x . a . l j . t . a t q Z p . h j . a
Z a Z p . s . j . q . \ j . d . j . Z j . a . x . q .
q Z a a P Z a . d . j . t . q . t . h P . t x . j . s .
Z a j Z d a . j . t . q . t . h P . t x . j . s .
d .
a p . q . j . Z p . Z . j . q . x . j . a . p . O t . t . p j . j .
p . q . j . Z p . Z . j . q . x . j . a . p . O t . t . p j . j .
j . s . t p . j . p . \ j . a . R . Z h j . a . x . j . Z
p . q . p . ? Z . t p . p . Z . a . Z j .
j . p . j . ? . j . q . Z . s . p . a) p p . j . p . d . a j . d
Z h . Z h . Z . t . Rhodococcus equi . p . s . x . x .
Z . j . a . p . q . x . j . j . \ j . p . ? .
Z . a . p . q . x . j . j . \ j . p . ? .
p . Z . a . R . p p . j . a . j . j . q . Z . j . a
p . s . Z a . Z

Discussion

.
P . s . j . a s a Z Z h . Z h . j . Z
j . x . p a p . p . p . Z Z h . Z h . Z j . Z
p . p . j . j . Z . a . p . j . a . p . p
Z . a . p . Z . a . \ j . p . Z j . x . p . j . p .
Z . x . Z j . a . \ p . Z . d . j . Z . h . q . p . \ j . Z j . a
q . x . Z j . q . x . \ Z Z h . Z h . Z p . j . s . s . q . Z j . p
p . p . Z . s . x . j . p p . h . Z a . j . p . ? . x . d . Z Z
h . Z h . Z . x . p . j . j . x . j . q . j . a s a Z p .

p j . . . j j j . Z p . Z . a t . j j x j . p . p p .
j . a . j . p p . Z . j . Z . q . j .
? . s . a . Z . Z p . j . Z Z h . Z h . Z j . k . t .
p . \ . s . a . Z . Z p . j . Z . j . h . Z j . a . a . R .
Z . p . Z . a . j . j . Z . j . I ? . p . x . p .
Z . Z . x . p . Z . p . \ . q . \ . I ? .
p . p . j . Z . x . p . j . Z . p . p . j . p . Z . j . p
t . j . Z . R . x . x . p . j . Z . j . R . a . Z . Z
j . Z ? . p a . j . Z . p . j . d . j . a . Z . Z
a . R . a . j . a . \ . Z . Z . Z . j . j . p a . j . x .
a . j . Z . j . p t . Z . Z . Z . j . j . p a . j . x .
q . j . a p . a . p x j . j . j . Z . s . Z a . p . j . j . d
Z . j . R . j . j . Z . j . p . p . a . t . j . Z Z
h . Z h . p Escherichia coli . Z . Z . p . Z Z p
Klebsiella pneumoniae . j . a Proteus mirabilis
Z . Z .
j . j . a . Z . a . j . s . s . t . Z . Z
x . t . a . a . t . Z . j . p t . s . Z
j . Z Z h . Z h . Z . j . a . x . a . j . j .
a . j . Z . p . j . a . s . a . p . t . Z . j . Z .
Z . ? . Z . p . t . Z . x . Z . j . Z . t . p . Z
j . R . Z . a . Z . j . a . O . a . Z . x . p . x . t . d . Z j . R
j . j . j . Z . x . x . x . x . Z . j . p
q . p . Z j . d . j . ? . a . Z . s . a . j . a a . j . q .
j . Z . Z . t . Z . x . d . j . a . j . p . Z . p . p
j . Z Z h . Z h . Z . s . x . j . p . p . j . Z . Z . a . d .
j . p . j . d . Z . Z . j . x . x . h . Z . p . x . Z j .
j . p . d . Z Z h . Z h . Z . j . p . h . Z . p . x . Z j .
j . a . p . t . Z . j . a . x . x . p . Z . a . t . Z
x . j . . p . \ Z . Z . j . p . j . j . Z . d . j . p . a

Table 3 Proven HIV cases with malakoplakia

Reference	Age	Sex	Country	Immune status/ CD4 count cells/ cubic millimeter	Symptoms	Location	Culture	Medication received	Outcome
[5]	52	Male	Czech Republic	AIDS/ not reported	Productive cough and fever	Pulmonary	Rhodococcus equi	Not reported	Not reported
[6]	41	Male	United States	AIDS/ 44	Mass on scalp	Brain	No organism identified	Ciprofloxacin, Trimethoprim-sulfamethoxazole	Cure
[7]	39	Male	France	AIDS/ 5	Fever, weight loss, chronic diarrhea	Colon	Shigella boydii	Clarithromycin, ciprofloxacin	Cure
[8]	25	Male	Mexico	AIDS/ 7	Productive cough, weight loss	Pulmonary	Rhodococcus equi	Rifampicin, vancomycin, ciprofloxacin	Cure
[9]	45	Female	India	AIDS/ 173	Skin ulcer	Cutaneous	Staphylococcus Aureus	Ciprofloxacin	Cure
[10]	30	Male	United States	AIDS/ 35	Productive cough, weight loss and fever	Pulmonary	Rhodococcus equi	Rifabutin, azithromycin	Lost follow up
[11]	47	Male	United States	AIDS/ 33	Stridor and non-productive cough	Trachea	Rhodococcus equi	Rifampicin, azithromycin	Relapsed
[12]	45	Male	United States	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Not reported	Cure
[13]	25	Male	United States	AIDS/ not reported	Dyspnea, fever, cough, weight loss	Pulmonary	Rhodococcus equi	Rifampicin, erythromycin	Cure
[14]	49	Male	France	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Erythromycin, netilmicin	Died
[15]	45	Male	Canada	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Vancomycin, imipenem, doxycycline, erythromycin	Cure
[16]	40	Male	South Korea	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Not reported	Not reported
	45	Male	South Korea	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Not reported	Not reported
	50	Male	South Korea	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Not reported	Not reported
	50	Male	South Korea	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Not reported	Not reported
[17]	34	Male	France	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Vancomycin, imipenem, rifampicin, clarithromycin, teicoplanin	Cure
[18]	36	Female	United States	AIDS/ not reported	Cough, Fever, dysphagia	Pulmonary	Rhodococcus equi	Vancomycin, erythromycin	Lost follow up
[19]	49	Male	United States	AIDS/ not reported	Cough, fever, fatigue	Pulmonary	Rhodococcus equi	Ciprofloxacin	Lost follow up
[20]	37	Male	United States	AIDS/ not reported	Cough, fever, fatigue	Pulmonary	Rhodococcus equi	Not reported	Died
	48	Male	United States	AIDS/ not reported	Cough, fever, chest pain	Pulmonary	Rhodococcus equi	Not reported	Died
[21]	33	Male	United States	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Ciprofloxacin, erythromycin	Died
	41	Male	United States	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Vancomycin, erythromycin	Died
	43	Male	United States	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Erythromycin	Died
[22]	23	Male	Brazil	AIDS/ not reported	Not available	Pulmonary	Rhodococcus equi	Erythromycin	Lost follow up
[23]	29	Male	Spain	AIDS/ not reported	Fever, hemoptysis	Pulmonary	Rhodococcus equi	Imipenem, rifampicin, ciprofloxacin, doxycycline	Cure

Conclusion

Acknowledgements

None.

Author contributions

M.A. and M.M. Wrote the manuscript. N.E., H.K., S.A. and Y.A. Reviewed the manuscript.

Funding

This study did not receive any funding.

Data availability

The data that support the findings of this study are openly available.

Declarations

Ethics approval and consent to participate

The authors did not seek approval from an ethics committee.

Consent for publication

Available upon request.

Competing interests

The authors declare no competing interests.

Received: 11 August 2023 / Accepted: 2 January 2024

Published online: 07 January 2024

References

1. Thomson-Walker J, Barrington FJ. Case of Malakoplakia. *Proc R Soc Med.* 1923;16(Sect Urol):32–4. PMID: 19983418; PMCID: PMC2103215.

2. Purnell SD, Davis B, Burch-Smith R, Coleman P. Renal malakoplakia mimicking a malignant renal carcinoma: a patient case with literature review. *BMJ Case Rep.* 2015;2015:bcr2014208652. <https://doi.org/10.1136/bcr-2014-208652>. PMID: 26177998; PMCID: PMC4513562.
3. Bdou NI, NaPombejara C, Sagawa A, Ragland C, Stechschulte DJ, Nilsson U, Gourley W, Watanabe I, Lindsey NJ, Allen MS. Malakoplakia: evidence for monocyte lysosomal abnormality correctable by cholinergic agonist in vitro and in vivo. *N Engl J Med.* 1977;297(26):1413–9. <https://doi.org/10.1056/NEJM197712292972601>. PMID: 200843.
4. van Crevel R, Curfs J, van der Ven AJ, Assmann K, Meis JF, van der Meer JW. Functional and morphological monocyte abnormalities in a patient with malakoplakia. *Am J Med.* 1998;105(1):74–7. [https://doi.org/10.1016/s0002-9343\(98\)00130-2](https://doi.org/10.1016/s0002-9343(98)00130-2). PMID: 9688025.
5. Cesk, 2Rozsypal H, Aster V, Stahiková M, Horová B. Infekce bakterií *Rhodococcus equi* u osob infikovaných virem lidské imunodeficiency (HIV) [*Rhodococcus equi* infection in subjects infected with human immunodeficiency virus (HIV)]. *Cas Lek* 007;146(2):163–7. Czech. PMID: 17373114.
6. Toubes-Klingler E, Prabhu VC, Bernal K, Poage D, Swindells S. Malakoplakia of the cranium and cerebrum in a human immunodeficiency virus-infected man. Case report. *J Neurosurg.* 2006;104(3):432–5. <https://doi.org/10.3171/jns.2006.104.3.432>. PMID: 16572658.
7. Raguin G, Nemeth J, Wassef M, Aerts J, Salmeron M, Desplaces N, Belec L. Identification of *Shigella boydii* in colonic malakoplakia by universal bacterial 16S ribosomal DNA-based amplification in a human immunodeficiency virus-infected patient. *Clin Infect Dis.* 1999;28(1):142–3. <https://doi.org/10.1086/517178>. PMID: 10028087.
8. Ahumada VH, Ortiz-Monasterio I, Hernandez JL, Peralta AB. Pulmonary malakoplakia by *Rhodococcus equi* in an HIV-Infected patient in Mexico: a Case Report. *Case Rep Infect Dis.* 2020;2020:3131024. <https://doi.org/10.1155/2020/3131024>. PMID: 32318299; PMCID: PMC7166268.
9. Savant SR, Amladi ST, Kangle SD, Wadhwa SL, Nayak CS. Cutaneous malakoplakia in an HIV-positive patient. *Int J STD AIDS.* 2007;18(6):435–6. <https://doi.org/10.1258/095646207781024801>. PMID: 17609043.
10. Krie.malakutaneous ~~ak~~ Langes9999ng as>>BDCndobID 888>chi9.724395751 497.075805664 Tm

19. de Peralta-Venturina MN, Clubb FJ, Kielhofner MA. Pulmonary malacoplakia associated with *Rhodococcus equi* infection in a patient with acquired immunodeficiency syndrome. *Am J Clin Pathol*. 1994;102(4):459–63. <https://doi.org/10.1093/ajcp/102.4.459>. PMID: 7942603.
20. Scott MA, Graham BS, Verrall R, Dixon R, Schaener W, Tham KT. *Rhodococcus equi* an increasingly recognized opportunistic pathogen. Report of 12 cases and review of 65 cases in the literature. *Am J Clin Pathol*. 1995;103(5):649–55. <https://doi.org/10.1093/ajcp/103.5.649>